DOCSLIB.ORG

NORSK LOVTIDEND Avd

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
NORSK LOVTIDEND Avd NORSK LOVTIDEND Avd. I Lover og sentrale forskrifter mv. Utgitt i henhold til lov 19. juni 1969 nr. 53. Kunngjort 19. mai 2021 kl. 15.10 PDF-versjon 6. juli 2021 28.04.2021 nr. 1536 Forskrift om endring i forskrift om stønad til dekning av utgifter til viktige legemidler mv. (blåreseptforskriften) Hjemmel: Fastsatt av Helsedirektoratet 28. april 2021 med hjemmel i forskrift 28. juni 2007 nr. 814 om stønad til dekning av utgifter til viktige legemidler mv. (blåreseptforskriften) i § 1b tredje, jf. annet ledd. I I forskrift 28. juni 2007 nr. 814 om stønad til dekning av utgifter til viktige legemidler mv. (blåreseptforskriften) gjøres følgende endring: Oppdatert liste over legemidler folketrygden ikke yter stønad til og som omfattes av § 1b annet ledd legges som vedlegg til forskriften: Preparatnavn Virkestoff ATC-kode Dato for ikrafttredelse Alle Natriumhydrogenkarbonat A02AH 01.09.2020 Alle Atropin A03BA01 15.07.2019 Alle Maralixibat A05AX04 01.06.2021 Alle Odevixibat A05AX05 01.03.2021 Alle Kenodeoksykolsyre A05AA01 01.02.2019 Alle Kolsyre A05AA03 01.05.2019 Alle Obetikolsyre A05AA04 01.02.2019 Jorveza Budesonid A07EA06 01.08.2018 Alle Fenfluramin A08AA02 01.02.2020 Alle Setmelanotide A08AA12 01.06.2021 Renavit Vitamin B og andre komb. A11EX 01.09.2020 Qizenday D-biotin (vit H) A11HA05 15.07.2017 For ev. rettelser se nederst i den elektroniske versjonen: https://lovdata.no/LTI/forskrift/2021-04-28-1536 2 Sibnayal Kaliumsitrat og Kaliumhydrogenkarbonat A12BA30 01.10.2020 Alle Avalglucosidase alfa A16 01.03.2021 Alle Lonafarnib A16A 01.12.2020 Alle Imiglukerase A16AB02 01.02.2019 Alle Agalsidase alfa A16AB03 01.02.2019 Alle Agalsidase beta A16AB04 01.02.2019 Alle Laronidase A16AB05 01.02.2019 Alle Alglukosidase alfa A16AB07 01.02.2019 Alle Galsulfase A16AB08 01.02.2019 Alle Idursulfase A16AB09 01.02.2019 Alle Velaglukerase alfa A16AB10 01.02.2019 Alle Elosulfase alfa A16AB12 01.02.2019 Alle Asfotase alfa A16AB13 01.02.2019 Alle Sebelipase A16AB14 01.05.2019 Alle Velmanase alfa A16AB15 01.02.2018 Alle Cerliponase alfa A16AB17 02.01.2018 Alle Vestronidase alfa A16AB18 01.02.2018 Alle Pegvaliase A16AB19 01.11.2018 Alle Natrium-fenylbutyrat A16AX03 01.02.2019 Alle Nitisinon A16AX04 01.02.2019 Alle Sinkacetatdihydrat A16AX05 01.02.2019 Alle Miglustat A16AX06 01.02.2019 Alle Sapropterin dihydroklorid A16AX07 01.02.2019 Alle Teduglutid A16AX08 01.02.2019 Alle Glycerolfenylbutyrat A16AX09 01.02.2018 Alle Eliglustat A16AX10 01.02.2019 Alle Trientine A16AX12 01.02.2019 Alle Migalastat A16AX14 01.02.2019 Alle Telotristat etiprate A16AX15 01.02.2018 Alle Givosiran A16AX16 01.02.2020 Alle Lumasiran A16AX18 01.03.2021 For ev. rettelser se nederst i den elektroniske versjonen: https://lovdata.no/LTI/forskrift/2021-04-28-1536 3 Alle L-glutamin A16AA03 01.11.2018 Alle Cysteaminbitartrat A16AA04 01.02.2019 Alle Kargluminsyre A16AA05 01.02.2019 Alle Betain, vannfritt A16AA06 01.02.2019 Alle Metreleptin A16AA07 01.10.2020 Alle Epoprostenol B01AC09 01.01.2017 Ventavis Iloprost B01AC11 01.01.2017 Alle Treprostinil B01AC21 01.01.2017 Alle Seleksipag B01AC27 01.01.2017 Alle Defibrotid B01AX01 01.02.2019 Alle Kaplacizumab B01AX07 02.01.2018 Alle Valoctocogene roxaparvovec B02 01.10.2020 Alle Fibrinogen, human B02BB01 01.01.2016 Alle* Kombinasjoner med fibrinogen, human B02BC30 01.02.2018 Alle Koagulasjonsfaktor II, VII, IX og X i kombinasjon B02BD01 01.01.2016 Alle Koagulasjonsfaktor VIII B02BD02 01.01.2016 Alle Faktor VIII-inhibitor bypass-aktivitet B02BD03 01.01.2016 Alle Koagulasjonsfaktor IX B02BD04 01.01.2016 Alle Von Willebrands faktor og koagulasjonsfaktor VIII i B02BD06 01.01.2016 kombinasjon Alle Koagulasjonsfaktor XIII B02BD07 01.01.2016 Alle Eptacog alfa (aktivert) B02BD08 01.01.2016 Alle Von Willebrands faktor B02BD10 01.01.2016 Alle Katridekakog B02BD11 01.01.2016 Alle Koagulasjonsfaktor X B02BD13 15.07.2016 Alle Koagulasjonsfaktor VIII B02BD14 15.04.2016 Alle Romiplostim B02BX04 01.02.2019 Alle Eltrombo-pagolamin B02BX05 01.02.2019 Alle Emicizumab B02BX06 01.08.2018 Alle Lusutrombopag B02BX07 01.11.2018 Alle Avatrombopag B02BX08 01.01.2019 For ev. rettelser se nederst i den elektroniske versjonen: https://lovdata.no/LTI/forskrift/2021-04-28-1536 4 Alle Fostamatinib B02BX09 01.04.2019 Alle Erytropoietin B03XA01 01.01.2016 Alle Darbepoetin alfa B03XA02 01.01.2016 Alle Metoksypolyetylen-glykol-epoetin beta B03XA03 01.01.2016 Alle Roxadustat B03XA05 01.12.2020 Alle Luspatercept B03XA06 01.02.2020 Alle Gelatinforbindelser B05AA06 01.12.2020 Alle C1-inhibitor B06AC01 01.02.2019 Alle Icatibantacetat B06AC02 01.02.2019 Alle Conestat alfa B06AC04 01.02.2019 Alle Lanadelumab B06AC05 01.11.2018 Alle Berotralstat B06AC06 01.06.2021 Alle Krizanlizumab B06AX01 01.02.2020 Alle Betibeglogene autotemcel B06AX02 01.04.2019 Alle Meksiletin C01BB02 01.02.2019 Alle Angiotensin II C01CX09 01.04.2019 Alle Bosentan C02KX01 01.01.2017 Alle Ambrisentan C02KX02 01.01.2017 Alle Macitentan C02KX04 01.01.2017 Alle Riociguat C02KX05 01.01.2017 Jinarc Tolvaptan C03XA01 01.02.2019 Alle Landiololhydroklorid C07AB14 01.10.2020 Alle Volanesorsen sodium C10AX 01.05.2018 Alle Lomitapid C10AX12 01.02.2019 Alle Evinacumab C10AX17 01.06.2021 Alle Afamelanotide D02BB02 02.01.2018 Alle Bromelen D03BA03 01.05.2019 Alle Dimetylfumarat D05BX- 15.11.2016 Alle Fumarsyrederivater, kombinasjon D05BX51 01.05.2018 Alle Dupilumab D11AH05 01.02.2018 Alle Tralokinumab D11AH07 01.12.2020 For ev. rettelser se nederst i den elektroniske versjonen: https://lovdata.no/LTI/forskrift/2021-04-28-1536 5 Alle Abrocitinib D11AH08 01.06.2021 Alle Misoprostol G02AD06 02.01.2018 Granpidam Sildenafil G04BE03 01.12.2017 Mysildecard Sildenafil G04BE03 01.01.2017 Orisild Sildenafil G04BE03 01.01.2017 Revatio Sildenafil G04BE03 01.01.2017 Adcirca Tadalafil G04BE08 01.01.2017 Tadalafil AOP Tadalafil G04BE08 01.12.2020 Tadalafil Tadalafil G04BE08 01.01.2017 Accord** Alle Lonapegsomatropin H01A 01.06.2021 Alle Somatropin H01AC01 01.01.2016 Alle Mecasermin H01AC03 01.01.2016 Alle Somapacitan H01AC07 01.06.2020 Alle Pegvisomant H01AX01 01.02.2019 Alle Oktreotid H01CB02 01.02.2019 Alle Lanreotid H01CB03 01.02.2019 Alle Pasireotidpamoat H01CB05 01.02.2019 Neofordex Deksametason H02AB02 01.02.2019 Plenadren Hydrokortison H02AB09 01.02.2019 Alkindi Hydrokortison H02AB09 01.01.2019 Efmody Hydrokortison H02AB09 01.06.2021 Alle Osilodrostat H02CA02 15.07.2019 Alle* Ketokonazol H02CA03 01.02.2019 Alle Cinacalcet H05BX01 01.09.2020 Alle Parikalsitol H05BX02 01.09.2020 Parsabiv Etelkalsetid H05BX04 02.01.2018 Alle Paratyroidea-hormon H05AA03 01.02.2019 Alle Meropenem og vaborbactam J01DH52 15.02.2018 Alle Imipenem/cilastatin/relebactam J01DH56 01.11.2019 Alle Cefiderocol J01DI04 01.02.2020 For ev. rettelser se nederst i den elektroniske versjonen: https://lovdata.no/LTI/forskrift/2021-04-28-1536 6 Alle Plazomicin J01GB14 15.07.2019 Alle Eravacyklin J01AA13 01.05.2018 Alle Isavukonazol J02AC05 01.02.2019 Alle Caspofungin J02AX04 01.04.2019 Alle Remdesivir J05AB16 01.06.2021 Alle Sakinavir J05AE01 01.01.2018 Alle Indinavir J05AE02 01.01.2018 Alle Ritonavir J05AE03 01.01.2018 Alle Atazanavir J05AE08 01.01.2018 Alle Tipranavir J05AE09 01.01.2018 Alle Darunavir J05AE10 01.01.2018 Alle Zidovudin J05AF01 01.01.2018 Alle Stavudin J05AF04 01.01.2018 Alle Lamivudin J05AF05 01.01.2018 Alle Abakavir J05AF06 01.01.2018 Alle Tenofovirdisoproksil J05AF07 01.01.2018 Alle Adefovirdipivoksil J05AF08 01.01.2018 Alle Emtricitabin J05AF09 01.01.2018 Alle Entekavir J05AF10 01.01.2018 Alle Telbivudine J05AF11 01.01.2018 Alle Tenofoviralafenamid J05AF13 01.01.2018 Alle Nevirapin J05AG01 01.01.2018 Alle Efavirenz J05AG03 01.01.2018 Alle Etravirin J05AG04 01.01.2018 Alle Rilpivirin J05AG05 01.01.2018 Alle Doravirin J05AG06 01.06.2018 Dectova Zanamivir J05AH01 01.08.2018 Alle* Raltegravir J05AJ01 01.01.2018 Alle* Dolutegravir J05AJ03 01.01.2018 Alle Kabotegravir J05AJ04 01.04.2020 Alle Ribavirin J05AP01 01.01.2018 For ev. rettelser se nederst i den elektroniske versjonen: https://lovdata.no/LTI/forskrift/2021-04-28-1536 7 Alle Simeprevir J05AP05 01.01.2016 Alle Daklatasvir J05AP07 01.01.2016 Alle Sofosbuvir J05AP08 01.01.2016 Alle Dasabuvir J05AP09 01.01.2016 Alle Sofosbuvir og ledipasvir J05AP51 01.01.2016 Alle Ombitasvir, paritaprevir og ritonavir J05AP53 01.01.2016 Alle Elbasvir/grazoprevir J05AP54 15.05.2016 Alle Sofosbuvir og velpatasvir J05AP55 15.07.2016 Alle Sofosbuvir, velpatasvir og voksilaprevir J05AP56 15.09.2017 Alle Glecaprevir, pibrentasvir J05AP57 15.09.2017 Alle Lamivudin og zidovudin J05AR01 01.01.2018 Alle Abakavir og lamivudin J05AR02 01.01.2018 Alle Emtricitabin og tenofovirdisoproksil J05AR03 01.01.2018 Alle Abakavir, lamivudin og zidovudin J05AR04 01.01.2018 Alle Emtricitabin, tenofovirdisoproksil og efavirenz J05AR06 01.01.2018 Alle Emtricitabin, tenofovirdisoproksil og rilpivirin J05AR08 01.01.2018 Alle Emtricitabin, tenofovirdisoproksil, elvitegravir og J05AR09 01.01.2018 kobicistat Alle Lopinavir og ritonavir J05AR10 01.01.2018 Alle Dolutegravir, abakavir og lamivudin J05AR13 01.01.2018 Alle Darunavir og kobicistat J05AR14 01.01.2018 Alle Atazanavir og kobicistat J05AR15 01.01.2018 Alle Emtricitabin og tenofoviralafenamid J05AR17 01.01.2018 Alle Emtricitabin, tenofoviralafenamid, elvitegravir og J05AR18 01.01.2018 kobicistat Alle Emtricitabin, tenofoviralafenamid og rilpivirin J05AR19 01.01.2018 Alle Emtricitabine, tenofovir alafenamid og bictegravir J05AR20 01.02.2018 Alle Dolutegravir og rilpivirinhydroklorid J05AR21 01.02.2018 Alle Darunavir,kobicistat,emtricitabine og tenofovir J05AR22 15.02.2018 alafenamid Alle
Load more

Recommended publications
  • United States Atopic Dermatitis (AD) Market Report 2021
    Source: Research and Markets July 28, 2021 04:08 ET United States Atopic Dermatitis (AD) Market Report 2021 Dublin, July 28, 2021 (GLOBE NEWSWIRE) -- The "Atopic Dermatitis (AD) - US Market Insight, Epidemiology and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering. This 'Atopic Dermatitis (AD) - Market Insights, Epidemiology and Market Forecast- 2030' report delivers an in- depth understanding of the Atopic Dermatitis (AD), historical and forecasted epidemiology as well as the Atopic Dermatitis (AD) market trends in the United States. Key Findings The total prevalent population of AD in the United States was estimated to be 32,197,083 in 2020. The total diagnosed prevalent population of AD in the United States was estimated to be 25,091,967 in 2020. The prevalent population of AD in the United States is expected to increase at a CAGR of 0.58% during the study period 2018-2030. In the United States, the total number of adult cases of AD comprised of 5,684,566 males and 9,421,907 females in 2020. The total number of cases of mild AD were 9,065,394 in the United States, in 2020, as compared to the cases of moderate and severe AD with 4,365,771 and 1,661,712 cases respectively, in adults. In children, the total number of cases of mild AD were 6,690,281, in 2020, as compared to the cases of moderate and severe AD with 2,596,228 and 698,985 cases respectively, in the United States. Report Highlights In the coming years, Atopic Dermatitis (AD) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
    [Show full text]
  • Inflarx N.V. 2020 Dutch Board Report
    InflaRx N.V. Dutch statutory board report and financial statements for the financial year ended December 31, 2020 - 1 - TABLE OF CONTENTS 1 Introduction ............................................................................................................................... 4 1.1 Preparation ................................................................................................................................. 4 1.2 Forward-looking statements ...................................................................................................... 4 2* Risk factors ................................................................................................................................ 7 2.1 Summary of key risk factors ...................................................................................................... 7 2.2 Risk factors ................................................................................................................................ 7 2.2.1 Risks related to our financial position and need for additional capital. ..................................... 7 2.2.2 Risks related to the discovery, development and commercialization of our product candidates. ................................................................................................................................................... 9 2.2.3 Risks related to our dependence on third parties ..................................................................... 20 2.2.4 Risks related to our intellectual property ................................................................................
    [Show full text]
  • Conference Reportpeer-Reviewed
    Medicom International Conference Series in Dermatology 28th EADV Congress European Academy of Dermatology and Venereology 9-13 october 2019 • Madrid • Spain EVIEWED R PEER- CONFERENCE CONFERENCE REPORT Late-Breaking News Emerging Therapies Spotlight on Psoriasis JAK inhibitors are a fascinating The IL-4/IL-13 blocker dupilumab Ten-year data from the ESPRIT novel drug class entering the der- leads to rapid itch reduction in registry shows the importance of matologic arena. The JAK1 and adolescents. The safety profile is achieving good control of moderate- JAK2 inhibitor baricitinib showed similar to that in adults. to-severe psoriasis. to be effective in patients with moderate-to-severe atopic derma- titis in a phase 3 trial. read more on PAGE 5 read more on PAGE 10 read more on PAGE 13 Editor Peter van de Kerkhof, Radboud University Medical Center, the Netherlands MEDIC AL PUBLISHERS Contents Letter from the Editor 3 Late-Breaking News 3 IL-17A blocker effective in paediatric psoriasis patients 3 Rituximab beats mycophenolate mofetil in pemphigus vulgaris COLOPHON 4 Novel JAK1/2 inhibitor shows remarkable efficacy in alopecia areata Editor Prof. Peter van de Kerkhof Radboud University Medical Center, 5 Acne highly influenced by climate, pollutants, and unhealthy diet the Netherlands 5 JAK inhibition plus TCS lead to high clearance rates in AD Advisory Board Prof. Margarida Gonçalo 6 No cancer risk with long-term use of calcineurin inhibitor in Coimbra University Hospital, Portugal children with AD Dr Tom Hillary UZ Leuven, Belgium 7 Green
    [Show full text]
  • Atopic Dermatitis: an Expanding Therapeutic Pipeline for a Complex Disease
    REVIEWS Atopic dermatitis: an expanding therapeutic pipeline for a complex disease Thomas Bieber 1,2,3 Abstract | Atopic dermatitis (AD) is a common chronic inflammatory skin disease with a complex pathophysiology that underlies a wide spectrum of clinical phenotypes. AD remains challenging to treat owing to the limited response to available therapies. However, recent advances in understanding of disease mechanisms have led to the discovery of novel potential therapeutic targets and drug candidates. In addition to regulatory approval for the IL-4Ra inhibitor dupilumab, the anti- IL-13 inhibitor tralokinumab and the JAK1/2 inhibitor baricitinib in Europe, there are now more than 70 new compounds in development. This Review assesses the various strategies and novel agents currently being investigated for AD and highlights the potential for a precision medicine approach to enable prevention and more effective long-term control of this complex disease. Atopic disorders Atopic dermatitis (AD) is the most common chronic inhibitors tacrolimus and pimecrolimus and more 1,2 A group of disorders having in inflammatory skin disease . About 80% of disease cases recently the phosphodiesterase 4 (PDE4) inhibitor cris- common a genetic tendency to typically start in infancy or childhood, with the remain- aborole. For the more severe forms of AD, besides the develop IgE- mediated allergic der developing during adulthood. Whereas the point use of ultraviolet light, current therapeutic guidelines reactions. These are atopic dermatitis, food allergy, allergic prevalence in children varies from 2.7% to 20.1% across suggest ciclosporin A, methotrexate, azathioprine and 3,4 rhino- conjunctivitis and countries, it ranges from 2.1% to 4.9% in adults .
    [Show full text]
  • Frontiers in Dermatology and Venereology - a Series of Theme Issues in Relation to the 100-Year Anniversary of Actadv
    ISSN 0001-5555 ActaDV Volume 100 2020 Theme issue ADVANCES IN DERMATOLOGY AND VENEREOLOGY A Non-profit International Journal for Interdisciplinary Skin Research, Clinical and Experimental Dermatology and Sexually Transmitted Diseases Frontiers in Dermatology and Venereology - A series of theme issues in relation to the 100-year anniversary of ActaDV Official Journal of - European Society for Dermatology and Psychiatry Affiliated with - The International Forum for the Study of Itch Immediate Open Access Acta Dermato-Venereologica www.medicaljournals.se/adv ACTA DERMATO-VENEREOLOGICA The journal was founded in 1920 by Professor Johan Almkvist. Since 1969 ownership has been vested in the Society for Publication of Acta Dermato-Venereologica, a non-profit organization. Since 2006 the journal is published online, independently without a commercial publisher. (For further information please see the journal’s website https://www. medicaljournals.se/acta) ActaDV is a journal for clinical and experimental research in the field of dermatology and venereology and publishes high- quality papers in English dealing with new observations on basic dermatological and venereological research, as well as clinical investigations. Each volume also features a number of review articles in special areas, as well as Correspondence to the Editor to stimulate debate. New books are also reviewed. The journal has rapid publication times. Editor-in-Chief: Olle Larkö, MD, PhD, Gothenburg Former Editors: Johan Almkvist 1920–1935 Deputy Editors: Sven Hellerström 1935–1969
    [Show full text]
  • Hidradenitis Suppurativa: Where We Are and Where We Are Going
    cells Review Hidradenitis Suppurativa: Where We Are and Where We Are Going Emanuele Scala 1,* , Sara Cacciapuoti 2 , Natalie Garzorz-Stark 1,3, Matteo Megna 2 , Claudio Marasca 2, Peter Seiringer 1,4, Thomas Volz 3, Kilian Eyerich 1,3,5,† and Gabriella Fabbrocini 2,† 1 Division of Dermatology and Venereology, Department of Medicine Solna and Center for Molecular Medicine, Karolinska Institutet, 17176 Stockholm, Sweden; [email protected] (N.G.-S.); [email protected] (P.S.); [email protected] (K.E.) 2 Department of Clinical Medicine and Surgery, University of Naples Federico II, 80131 Naples, Italy; [email protected] (S.C.); [email protected] (M.M.); [email protected] (C.M.); [email protected] (G.F.) 3 Department of Dermatology and Allergy, Technical University of Munich, 80802 Munich, Germany; [email protected] 4 Center for Allergy and Environment, Technical University, Helmholtz Center Munich, 80802 Munich, Germany 5 Unit of Dermatology, Department of Dermatology and Venereology, Karolinska University Hospital, 17176 Stockholm, Sweden * Correspondence: [email protected] † These authors contributed equally to the manuscript. Abstract: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease primarily affecting apocrine gland-rich areas of the body. It is a multifactorial disease in which genetic and environmental factors play a key role. The primary defect in HS pathophysiology involves follicular occlusion Citation: Scala, E.; Cacciapuoti, S.; of the folliculopilosebaceous unit, followed by follicular rupture and immune responses. Innate Garzorz-Stark, N.; Megna, M.; pro-inflammatory cytokines (e.g., IL-1β, and TNF-α); mediators of activated T helper (Th)1 and Th17 Marasca, C.; Seiringer, P.; Volz, T.; cells (e.g., IFN-γ, and IL-17); and effector mechanisms of neutrophilic granulocytes, macrophages, Eyerich, K.; Fabbrocini, G.
    [Show full text]
  • Aars Hot Topics Member Newsletter
    AARS HOT TOPICS MEMBER NEWSLETTER American Acne and Rosacea Society 201 Claremont Avenue • Montclair, NJ 07042 (888) 744-DERM (3376) • [email protected] www.acneandrosacea.org Like Our YouTube Page Visit acneandrosacea.org to Become an AARS Member and TABLE OF CONTENTS Donate Now on acneandrosacea.org/donate Industry News Mederma survey: America's got skin insecurities. ...................................................... 2 Our Officers Accure Acne seeks to raise up to $20 million through private placement offering ..... 2 J. Mark Jackson, MD AARS President New Medical Research Scientifically speaking: New directions in acne management, part 1. ........................ 3 Andrea Zaenglein, MD Tranexamic acid microinjections ................................................................................. 3 AARS President-Elect An increase in normetanephrine in hair follicles of acne lesions ................................ 4 Effects of ısotretinoin on the growth rate and thickness of the nail plate .................... 4 Joshua Zeichner, MD The effectiveness of botulinum toxin type A (BTX-A) in the treatment of facial skin .. 4 AARS Treasurer Efficacy and safety of non-surgical short-wave radiofrequency treatment ................. 5 Incidence and clinical implications of autoimmune thyroiditis ..................................... 5 Bethanee Schlosser, MD Topical 15% resorcinol is associated with high treatment satisfaction ....................... 6 AARS Secretary A novel azelaic acid formulation for the topical treatment of inflammatory
    [Show full text]
  • Personalized Medicine—Concepts, Technologies, and Applications in Inflammatory Skin Diseases
    Personalized medicine - concepts, technologies, and applications in inflammatory skin diseases Litman, T. Published in: APMIS - Journal of Pathology, Microbiology and Immunology DOI: 10.1111/apm.12934 Publication date: 2019 Document version Publisher's PDF, also known as Version of record Document license: CC BY Citation for published version (APA): Litman, T. (2019). Personalized medicine - concepts, technologies, and applications in inflammatory skin diseases. APMIS - Journal of Pathology, Microbiology and Immunology, 127(5), 386-424. https://doi.org/10.1111/apm.12934 Download date: 09. apr.. 2020 JOURNAL OF PATHOLOGY, MICROBIOLOGY AND IMMUNOLOGY APMIS 127: 386–424 © 2019 The Authors. APMIS published by John Wiley & Sons Ltd on behalf of Scandinavian Societies for Medical Microbiology and Pathology. DOI 10.1111/apm.12934 Review Article Personalized medicine—concepts, technologies, and applications in inflammatory skin diseases THOMAS LITMAN1,2 1Department of Immunology and Microbiology, University of Copenhagen, Copenhagen; 2Explorative Biology, Skin Research, LEO Pharma A/S, Ballerup, Denmark Litman T. Personalized medicine—concepts, technologies, and applications in inflammatory skin diseases. APMIS 2019; 127: 386–424. The current state, tools, and applications of personalized medicine with special emphasis on inflammatory skin diseases like psoriasis and atopic dermatitis are discussed. Inflammatory pathways are outlined as well as potential targets for monoclonal antibodies and small-molecule inhibitors. Key words: Atopic dermatitis; endotypes; immunology; inflammatory skin diseases; personalized medicine; precision medicine; psoriasis; targeted therapy. Thomas Litman, Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark. e-mail: [email protected] and Explorative Biology, Skin Research, LEO Pharna A/S, Ballerup, Denmark. e-mail: [email protected] INTRODUCTION – WHY? proteins (4, 5).
    [Show full text]
  • Lääkeaineiden Yleisnimet (INN-Nimet) 21.6.2021
    Lääkealan turvallisuus- ja kehittämiskeskus Säkerhets- och utvecklingscentret för läkemedelsområdet Finnish Medicines Agency Lääkeaineiden yleisnimet (INN-nimet) 21.6.
    [Show full text]
  • Inflarx N.V. (Exact Name of Registrant As Specified in Its Charter)
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of event requiring this shell company report Commission file number: 001-38283 InflaRx N.V. (Exact name of Registrant as specified in its charter) The Netherlands (Jurisdiction of incorporation or organization) Winzerlaer Str. 2 07745 Jena, Germany (+49) 3641 508 180 (Address of principal executive offices) Dr. Thomas Taapken, Chief Financial Officer Tel: (+49) 89 4141 897 800 Fraunhoferstr. 22, 82152 Planegg-Martinsried, Germany (Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person) Copies to: Sophia Hudson Kirkland & Ellis LLP 601 Lexington Avenue New York, NY 10022 Phone: (212) 446-4750 Securities registered or to be registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Shares, nominal value €0.12 per share IFRX The NASDAQ Stock Market LLC Securities registered or to be registered pursuant to Section 12(g) of the Act: None Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act: None Indicate the number of outstanding shares of each of the issuer’s classes of capital or common stock as of the close of the period covered by the annual report.
    [Show full text]
  • NETTER, Jr., Robert, C. Et Al.; Dann, Dorf- (21) International Application
    ll ( (51) International Patent Classification: (74) Agent: NETTER, Jr., Robert, C. et al.; Dann, Dorf- C07K 16/28 (2006.01) man, Herrell and Skillman, 1601 Market Street, Suite 2400, Philadelphia, PA 19103-2307 (US). (21) International Application Number: PCT/US2020/030354 (81) Designated States (unless otherwise indicated, for every kind of national protection av ailable) . AE, AG, AL, AM, (22) International Filing Date: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, 29 April 2020 (29.04.2020) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, (25) Filing Language: English DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, (26) Publication Language: English KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, (30) Priority Data: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 62/840,465 30 April 2019 (30.04.2019) US OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, (71) Applicants: INSTITUTE FOR CANCER RESEARCH TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW. D/B/A THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER [US/US]; 333 Cottman Av¬ (84) Designated States (unless otherwise indicated, for every enue, Philadelphia, PA 191 11-2497 (US). UNIVERSTIY kind of regional protection available) . ARIPO (BW, GH, OF KANSAS [US/US]; 245 Strong Hall, 1450 Jayhawk GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, Boulevard, Lawrence, KS 66045 (US).
    [Show full text]
  • Topical and Systematic Treatment of Atopic Dermatitis to Inform a Clinical Practice Guideline
    Topical and Systemic Treatment of Atopic Dermatitis Results of Topic Selection Process & Next Steps The nominator American Academy of Dermatology, is interested in a new evidence review on Topical and Systematic Treatment of Atopic Dermatitis to inform a clinical practice guideline. We identified several review(s) covering part of the scope of the nomination, therefore, a new review would be partially duplicative of an existing product. For the questions not covered by existing reviews, there is limited original research. No further activity on this nomination will be undertaken by the Effective Health Care (EHC) Program. Topic Brief Topic Numbers and Name: #0804, 0805, 0806 Topical and Systemic Treatment of Atopic Dermatitis Nomination Date: 7/09/2018 Topic Brief Date: 10/11/2018 Authors Elise Berliner Conflict of Interest: None of the investigators have any affiliations or financial involvement that conflicts with the material presented in this report. 1 Background Atopic dermatitis is a common chronic skin condition that causes itchy scaly red patches. The 1-year US prevalence of AD was estimated at 12.98% in children in 2007-2008 and 7.2%-10.2% in adults in 2010-20121. There is no biomarker, objective diagnostic test, or even standard nomenclature for describing atopic dermatitis and related conditions such as other forms of eczema. NIH has funded an initiative to harmonize outcome measures in atopic dermatitis.2 Patients with atopic dermatitis typically try to control their symptoms through supportive care including bathing and moisturizing ointments, wearing soft breathable fabrics and avoiding contact with allergens. The current American Academy of Dermatology guidelines do not recommend non-sedating antihistamines for atopic dermatitis, but recognize that sedating antihistamines may have value in controlling insomnia secondary to itching.
    [Show full text]